ProQR FY 2025 net loss rises 52% to EUR 42.2 million as cash falls 38% to EUR 92.4 million

Reuters03-12 19:05
ProQR FY 2025 net loss rises 52% to EUR 42.2 million as cash falls 38% to EUR 92.4 million

ProQR reported a FY 2025 net loss of EUR 42.2 million, or EUR 0.4 per diluted share. Cash and cash equivalents were EUR 92.4 million at year-end 2025, down 38% from the prior year-end. FY 2025 R&D costs rose 23% to EUR 44.7 million, while G&A costs increased 10% to EUR 15.1 million. Net cash used in operating activities was EUR 52.8 million, up 45%, and the company said it achieved USD 4.5 million in Eli Lilly collaboration milestones during FY 2025. Management said the cash position supports runway into mid-2027 and expects AX-0810 Phase 1 target engagement data in 1H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120700PRIMZONEFULLFEED1001169637) on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment